AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 6 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The major proteinase of Trypanosoma cruzi, cruzipain, showed promise as a vaccine component to prevent trypanosomiasis, according to a report in Infection and Immunity.
Anita R. Schnapp and colleagues at St. Louis University and Washington University in St. Louis, explained that they chose cruzipain for testing because it "is expressed by all developmental forms and strains of the parasite and stimulates potent humoral and cellular immune responses during infection in both humans and mice."
The investigators created a line of CD4+ T lymphocytes that were reactive to cruzipain and cultured the cells with T. cruzi-infected macrophages. The CD4+ cells secreted large quantities of interferon-gamma (IFN-gamma) that significantly suppressed parasite reproduction.
Mice that were vaccinated with a combination of recombinant cruzipain, interleukin-12 (IL-12), and antibodies specific for interleukin-4 (IL-4) generated a strong Th1 immune response and were protected against a lethal systemic challenge of T. cruzi. Mice vaccinated with an attenuated cruzipain-expressing Salmonella enterica serovar Typhi vaccine were protected against mucosal infection of T. cruzi.
"Overall, these data indicate that cruzipain is an important T. cruzi ...